COVID-19 Response at Fishpond

Read what we're doing...

Innovative drug development for headache disorders
By

Rating

Product Description
Product Details

Table of Contents

Screening models 1: Bolette Christiansen, Trine Kvist, Anders A. Jensen and Hans Brauner-Osborne: The human GABA transporter GAT-2 - From cloning to high throughput screening 2: Peter Goadsby: Low throughput preclinical models for headache 3: Messoud Ashina: Human models - screening models Trials methodology 4: Peer Tfelt-Hansen: Stricter success criteria, qualitative and quantitative end points: Acute vs. prevention trials 5: Carl G.H. Dahloef: Health related quality of life and similar end points 6: Michel D. Ferrari: Clinically relevant designs and outcome measures for acute migraine trials 7: E. Marchioni, S. Colnaghi, M. Versino, A. Pichiecchio, E. Tavazzi and G. Nappi: Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new HIS classification 8: Jes Olesen: Discussion summary: Trials methodology NO and spreading depression modulators 9: Boris A. Chizh: Inducible nitric oxide synthase and development of new migraine treatments 10: Kevin C. Brennan and Andrew C. Charles: Mechanisms of cortical spreading depression as targets for migraine therapy 11: Peter R. Blower and Paul C. Sharpe: Tonabersat 12: Nabih Ramadan: Discussion Summary: NO and spreading depression modulators CGRP and 5-HT modulators 13: Jes Olesen and Inger Jansen-Olesen: Calcitonin gene-related peptide (CGRP): relevance for migraine 14: Pramod Saxena: New 5-HT related drug targets 15: L. Juhl, L. Edvinsson, J. Olesen, I. Jansen-Olesen: Effect of two novel CGRP-binding compounds in a closed cranial window rat model 16: Jacob Moller Hansen, Alexandra Maria Rahmann, Troels Wienecke, Jes Olesen, Messoud Ashina: Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment 17: Rigmor Jensen: Discussion Summary: CGRP and 5-HT modulators Ion Channel modulators and antiepileptics 18: Arn M.J.M. van den Maagdenberg: Migraine: from genes to pathophysiology - transgenic mouse models of migraine 19: Inger Jansen-Olesen and Kenneth Beri Ploug: Katp channels and migraine 20: Michael Rogawski: Antiepileptic drugs and migraine 21: Pramod Saxena: Discussion Summary: Ion channel modulators and antiepileptics Other future targets for headache therapy 22: Kirk W Johnson, Eric S. Nisenbaum, Michael P. Johnson, Donna K. Dieckman, Amy Clemens-Smith, Edward R Siuda, Colin P. Dell, Veronique Dehlinger, Kevin J. Hudziak, Sandra A. Filla, Paul L. Ornstein, Nabih M Ramadan and David Bleakman: Innovative drug development for headache disorders - Glutamate 23: Beatriz Fioravanti & Todd Vanderah: The modulation of TRPV1 channels by cannabinoid1 receptors 24: Christian Waeber: Future targets for headache therapy: Prostanoids 25: Cristina Tassorelli, Rosaria Greco, Armando Perrotta, Simona Buscone, Giorgio Sandrini, Giuseppe Nappi: Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia - a study in the rat

Ask a Question About this Product More...
Write your question below:
Look for similar items by category
People also searched for
This title is unavailable for purchase as none of our regular suppliers have stock available. If you are the publisher, author or distributor for this item, please visit this link.
Item ships from and is sold by Fishpond World Ltd.
Back to top